CardioDx Receives $60,000,000 New Funding

  • Feed Type
  • Date
    5/11/2011
  • Company Name
    CardioDx
  • Mailing Address
    2500 Faber Place Palo Alto, CA 94303
  • Company Description
    Founded in 2004, CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
  • Website
    http://www.cardiodx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $60,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Funding will be used to expand reimbursement coverage in the United States for Corus™ CAD, the company’s blood-based gene expression test for obstructive coronary artery disease, and to continue development of future products in the field of cardiovascular genomic diagnostics.
  • M&A Terms
  • Venture Investor
    Longitude Capital Management
  • Venture Investor
    JPMorgan Partners
  • Venture Investor
    Acadia Woods Ventures
  • Venture Investor
    Artiman Ventures
  • Venture Investor
    Kleiner Perkins Caufield & Byers
  • Venture Investor
    Mohr Davidow Ventures
  • Venture Investor
    TPG Biotech
  • Venture Investor
    Pappas Ventures
  • Venture Investor
    DAG Ventures
  • Venture Investor
    Asset Management Company

By posting a comment, you agree to our terms and conditions.